Pernille H. Hemmingsen

Pernille H. Hemmingsen

Auto-generated profile, based on publicly available information

Pernille H. Hemmingsen

Egalet Denmark, Lejrvej 37-41, DK-3500 Værløse, Denmark

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2011 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
PHPernille H. Hemmingsen
Pernille H. Hemmingsen
AHAnne-Mette Haahr
Anne-Mette Haahr
CGChristine Gunnergaard
Christine Gunnergaard
JCJean-Michel Cardot
Jean-Michel Cardot
A novel abuse deterrent, prolonged release tablet formulation of Hydrocodone for once-daily dosing has been developed, based on the novel proprietary Egalet® ADPREM technology. The tablet is an injection molded polymer system consisting of an erodible matrix in which the Active Pharmaceutical Ingredient (API), such as Hydrocodone, is dispersed. The matrix is partly covered with a water-impermeable, non-erodible shell which leaves both ends of the cylindrical tablet exposed to erosion by the gastrointestinal (GI) fluid. In vivo–in vitro correlation (IVIVC) was initiated and validated with three formulations. A good internal predictability was observed for the three formulations. How the changing conditions in the GI tract influenced in vivo performance of an erosion based product was discussed. The validated IVIVC could be used to optimize the tablet formulation and to obtain a desired profile. In addition, this technique could help to establish the dissolution limits in which a certainty of bioequivalence is calculated. Based on this validated level A IVIVC, dissolution can be used as surrogate of bioequivalence for development, but also scale up post approval changes.